329 related articles for article (PubMed ID: 29982879)
1. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
Funikov SY; Rezvykh AP; Mazin PV; Morozov AV; Maltsev AV; Chicheva MM; Vikhareva EA; Evgen'ev MB; Ustyugov AA
Neurogenetics; 2018 Aug; 19(3):189-204. PubMed ID: 29982879
[TBL] [Abstract][Full Text] [Related]
2. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice.
Shelkovnikova TA; Peters OM; Deykin AV; Connor-Robson N; Robinson H; Ustyugov AA; Bachurin SO; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Skvortsova VI; Ling SC; Da Cruz S; Parone PA; Buchman VL; Ninkina NN
J Biol Chem; 2013 Aug; 288(35):25266-25274. PubMed ID: 23867462
[TBL] [Abstract][Full Text] [Related]
3. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
[TBL] [Abstract][Full Text] [Related]
4. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
6. ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.
King A; Troakes C; Smith B; Nolan M; Curran O; Vance C; Shaw CE; Al-Sarraj S
Acta Neuropathol Commun; 2015 Oct; 3():62. PubMed ID: 26452761
[TBL] [Abstract][Full Text] [Related]
7. Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice.
Lysikova EA; Funikov S; Rezvykh AP; Chaprov KD; Kukharsky MS; Ustyugov A; Deykin AV; Flyamer IM; Boyle S; Bachurin SO; Ninkina N; Buchman VL
Neurochem Res; 2020 May; 45(5):1168-1179. PubMed ID: 32157564
[TBL] [Abstract][Full Text] [Related]
8. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
[TBL] [Abstract][Full Text] [Related]
9. Characteristic Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic Lateral Sclerosis.
Ikenaka K; Ishigaki S; Iguchi Y; Kawai K; Fujioka Y; Yokoi S; Abdelhamid RF; Nagano S; Mochizuki H; Katsuno M; Sobue G
J Neuropathol Exp Neurol; 2020 Apr; 79(4):370-377. PubMed ID: 32142134
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic Lateral Sclerosis.
Shelkovnikova TA; An H; Skelt L; Tregoning JS; Humphreys IR; Buchman VL
Cell Rep; 2019 Dec; 29(13):4496-4508.e4. PubMed ID: 31875556
[TBL] [Abstract][Full Text] [Related]
11. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay.
Kamelgarn M; Chen J; Kuang L; Jin H; Kasarskis EJ; Zhu H
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11904-E11913. PubMed ID: 30455313
[TBL] [Abstract][Full Text] [Related]
12. Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis.
Rademakers R; Stewart H; Dejesus-Hernandez M; Krieger C; Graff-Radford N; Fabros M; Briemberg H; Cashman N; Eisen A; Mackenzie IR
Muscle Nerve; 2010 Aug; 42(2):170-6. PubMed ID: 20544928
[TBL] [Abstract][Full Text] [Related]
13. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis.
Scekic-Zahirovic J; Oussini HE; Mersmann S; Drenner K; Wagner M; Sun Y; Allmeroth K; Dieterlé S; Sinniger J; Dirrig-Grosch S; René F; Dormann D; Haass C; Ludolph AC; Lagier-Tourenne C; Storkebaum E; Dupuis L
Acta Neuropathol; 2017 Jun; 133(6):887-906. PubMed ID: 28243725
[TBL] [Abstract][Full Text] [Related]
14. Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif.
Robinson HK; Deykin AV; Bronovitsky EV; Ovchinnikov RK; Ustyugov AA; Shelkovnikova TA; Kukharsky MS; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Bachurin SO; Buchman VL; Ninkina NN
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):402-9. PubMed ID: 25991062
[TBL] [Abstract][Full Text] [Related]
15. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.
Mitchell JC; McGoldrick P; Vance C; Hortobagyi T; Sreedharan J; Rogelj B; Tudor EL; Smith BN; Klasen C; Miller CC; Cooper JD; Greensmith L; Shaw CE
Acta Neuropathol; 2013 Feb; 125(2):273-88. PubMed ID: 22961620
[TBL] [Abstract][Full Text] [Related]
17. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
[TBL] [Abstract][Full Text] [Related]
18. Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.
Pelaez MC; Desmeules A; Gelon PA; Glasson B; Marcadet L; Rodgers A; Phaneuf D; Pozzi S; Dutchak PA; Julien JP; Sephton CF
Acta Neuropathol Commun; 2023 Nov; 11(1):182. PubMed ID: 37974279
[TBL] [Abstract][Full Text] [Related]
19. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
20. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.
Mackenzie IR; Ansorge O; Strong M; Bilbao J; Zinman L; Ang LC; Baker M; Stewart H; Eisen A; Rademakers R; Neumann M
Acta Neuropathol; 2011 Jul; 122(1):87-98. PubMed ID: 21604077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
